Conceptio › Archive › HAL (France)
HAL (France)open access

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

F. Griesinger et al.
HAL (France) · Papers · License: Open Access
Open Source ↗
celllungcancersmalltargetedtherapy
RET inhibition, 0, Non-small-cell lung cancer, Pralsetinib, Targeted therapy, Frontline therapy, 1, RET fusion
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗
Record · ID 161257
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.